Menu

TS Picks: October 24, 2016

Theranos’s bad blood tests; presidential science lessons; “three-parent” babies

Oct 24, 2016
Tracy Vence

PUBLIC DOMAIN PICTURES, CIRCE DENYER

Selections from The Scientist’s reading list

  • The Wall Street Journal spoke with patients who were affected by inaccurate Theranos blood tests. “Rattled patients who told The Wall Street Journal they sought more information about their results said they got no response, and weeks or months passed before Theranos told many patients that their results were unreliable.” The Wall Street Journal also reviewed an undisclosed report from the US Centers for Medicare and Medicaid Services, which found that 834 of 2,890 quality-control checks using the company’s proprietary Edison devices “exceeded the company’s threshold of two standard deviations from its average result,” the publication reported.

See “Theranos Restructuring with Research Focus

See “Theranos CEO Banned from Running Labs for Two Years

  • Science last week (October 20) offered “science lessons for the next president,” including backgrounders on evolving pathogens and applications of CRISPR.
     
  • Last month, New Scientist reported on the birth of the first baby to have been treated with mitochondrial replacement therapy (MRT). Now, “that ‘three-parent’ baby may soon have company—if it does not already,” Nature reported last week (October 29). “Numerous scientific groups and government agencies are debating whether the procedure should be allowed in clinical use. Most conclude that mitochondrial replacement should be performed only under the auspices of a clinical trial and with independent oversight.”

See “First MRT Baby Born

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.